According to the Zhitong Finance App, Insi Intelligence (03696.HK) announced that Rentosertib (also known as ISM001-055/INS018_055), the leading AI-driven innovative drug candidate in the company's pipeline, has completed the enrollment and administration of the first phase III clinical trial (GENESIS-IPF-3) at Peking Union Medical College Hospital; on the same day, Shanghai Pulmonary Hospital also completed its first patient enrollment in this trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.